scPharmaceuticals Inc. financial data

Symbol
SCPH on Nasdaq
Industry
Pharmaceutical Preparations
Location
25 Burlington Mall Road, Suite 203, Burlington, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 19, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 665 % -41.6%
Quick Ratio 103 % +55.4%
Debt-to-equity 384 % +300%
Return On Equity -438 % -350%
Return On Assets -90.5 % -82.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.3M shares +39.5%
Common Stock, Shares, Outstanding 50.1M shares +39.3%
Entity Public Float 274M USD +263%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 44.5M shares +15.6%
Weighted Average Number of Shares Outstanding, Diluted 44.5M shares +15.6%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 11.4M USD +198%
Research and Development Expense 12.1M USD +2.45%
Operating Income (Loss) -64.8M USD -16.9%
Net Income (Loss) Attributable to Parent -85.1M USD -55.4%
Earnings Per Share, Basic -1.91 USD/shares -34.5%
Earnings Per Share, Diluted -1.91 USD/shares -34.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75.7M USD +61.6%
Accounts Receivable, after Allowance for Credit Loss, Current 11.7M USD +161%
Inventory, Net 13.9M USD +57.3%
Assets, Current 106M USD +13.9%
Property, Plant and Equipment, Net 56K USD -3.45%
Operating Lease, Right-of-Use Asset 1.27M USD -9.14%
Assets 108M USD +13.8%
Accounts Payable, Current 3.88M USD -2.95%
Employee-related Liabilities, Current 5.2M USD +18.9%
Accrued Liabilities, Current 10.7M USD +20.2%
Liabilities, Current 14.9M USD +13.3%
Operating Lease, Liability, Noncurrent 1.1M USD -13.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 94.2M USD +64.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -366M USD -30.3%
Stockholders' Equity Attributable to Parent 13.3M USD -64.2%
Liabilities and Equity 108M USD +13.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.7M USD -7.32%
Net Cash Provided by (Used in) Financing Activities 13.7M USD
Net Cash Provided by (Used in) Investing Activities 29.3M USD +319%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 50.1M shares +39.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.6M USD +176%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 75.7M USD +61.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.47M USD -1.08%
Deferred Tax Assets, Valuation Allowance 94.1M USD +28.6%
Deferred Tax Assets, Gross 94.4M USD +27%
Operating Lease, Liability 1.34M USD -7.89%
Depreciation 20K USD -16.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -85.1M USD -55.3%
Lessee, Operating Lease, Liability, to be Paid 1.73M USD -13.6%
Property, Plant and Equipment, Gross 136K USD +14.3%
Operating Lease, Liability, Current 239K USD +35.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 376K USD +10.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 381K USD +12.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 388K USD -28.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 358K USD +2.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.38M USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 367K USD +2.51%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 5.44M USD +12.1%
Interest Expense 7.57M USD -6.81%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%